MARKET

NRXPW

NRXPW

Nrx Pharmaceuticals Inc
NASDAQ
0.1464
-0.0035
-2.33%
Closed 15:34 04/25 EDT
OPEN
0.2134
PREV CLOSE
0.1499
HIGH
0.2134
LOW
0.1450
VOLUME
27.62K
TURNOVER
0
52 WEEK HIGH
0.3900
52 WEEK LOW
0.0500
MARKET CAP
--
P/E (TTM)
-0.3677
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at NRXPW last week (0415-0419)?
Weekly Report · 3d ago
BUZZ-U.S. STOCKS ON THE MOVE-Ibotta, Blackstone, US health insurers
Wall Street's main stock indexes gained on Thursday. Dow Jones Industrial Average was up 0.11% at 37,793.34. Top three S&P 500 percentage gainers: Estee Lauder, United Airlines, Genuine Parts. Top two Nasdaq percentage losers: Las Vegas Sands and Tesla.
Reuters · 04/18 17:35
BUZZ-U.S. STOCKS ON THE MOVE-D.R. Horton, 23andMe, Copper miners
D.R. Horton, 23andMe, Copper miners rise as chip stocks rebound. Dow e-minis expected to open higher on Thursday. Investors await commentary from Federal Reserve officials on outlook for interest-rate cuts. 23andme rises after CEO considers taking firm private.
Reuters · 04/18 13:13
NRX PHARMACEUTICALS, INC. ANNOUNCES PRICING OF $2.0 MILLION UNDERWRITTEN PUBLIC OFFERING OF COMMON STOCK
Reuters · 04/18 12:30
BUZZ-U.S. STOCKS ON THE MOVE-U.S. chip stocks, Lithium Americas, Boeing Co
Futures for the S&P 500 and the Nasdaq gained on Thursday. Some chip stocks recouped losses after a sell-off. Investors await Federal Reserve policymakers' stance on interest-rate cuts. Lithium Americas, Boeing Co are among the day's losers.
Reuters · 04/18 11:15
NRX PHARMACEUTICALS, INC. ANNOUNCES PROPOSED UNDERWRITTEN PUBLIC OFFERING OF COMMON STOCK
Reuters · 04/17 20:45
NRX PHARMACEUTICALS, INC. (NASDAQ:NRXP) ANNOUNCES NEW DATA ON NRX-101 DEMONSTRATING NO DAMAGE TO INTESTINAL AND VAGINAL FLORA IN VALIDATED RODENT MODELS COMPARED TO STANDARD ANTIBIOTICS: POTENTIAL IMPLICATIONS FOR AVOIDANCE OF C. DIFFICILE INFECTIONS
Reuters · 04/17 12:30
NRX PHARMACEUTICALS INC - HTX-100 IS EXPECTED TO BE MARKETED BY HOPE THERAPEUTICS, INC., A WHOLLY OWNED SUBSIDIARY OF NRX
Reuters · 04/15 12:30
More
About NRXPW
NRX Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing therapeutics based on its N-methyl-D-aspartate (NMDA) platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and post-traumatic stress disorder (PTSD). The Company has two lead compounds, NRX-100, a proprietary presentation of ketamine and NRX-101, a fixed-dose combination of D-cycloserine (DCS) and lurasidone. The Company is developing NRX-101, a Food and Drug Administration (FDA)-designated investigational therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRX-101 is a combined NMDA/5-HT2A-targeted medicine designed to address both depression and suicidal ideation, consisting of an oral, fixed dose combination of DCS and lurasidone. Its NRX-100 is racemic ketamine, which is a generic anesthetic. The Company is also engaged in the development of its new product, NRX-102.

Webull offers NRX Pharmaceuticals Inc stock information, including NASDAQ: NRXPW real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NRXPW stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading NRXPW stock methods without spending real money on the virtual paper trading platform.